How important are T-cell chemokines in chronic manifestations of Lyme disease?
T-cell chemokines may play an important role in the development of persistent symptoms following Lyme disease. Research has identified CCL19 as a potential marker associated with Post-Treatment Lyme Disease Syndrome (PTLDS). :contentReference[oaicite:0]{index=0}
What Is CCL19?
CCL19 is a chemokine involved in regulating immune responses, particularly T-cell activity.
In early Lyme disease, CCL19 levels typically rise and then return to normal following treatment in most patients.
When CCL19 Remains Elevated
In approximately 14% of patients, CCL19 levels remain elevated despite standard antibiotic therapy.
These individuals were found to have a significantly higher risk of developing PTLDS.
Patients with CCL19 levels above a defined threshold had more than a 12-fold increased risk of persistent symptoms at 6 to 12 months.
What Is PTLDS?
Post-Treatment Lyme Disease Syndrome is characterized by ongoing symptoms such as:
- Fatigue
- Musculoskeletal pain
- Cognitive difficulties
- Reduced functional capacity
These symptoms can significantly affect quality of life.
What Might Elevated CCL19 Mean?
Elevated CCL19 levels may reflect an ongoing immune response.
Possible explanations include:
- Persistent bacterial antigens
- Immune system dysregulation
- An autoimmune component
- In some cases, possible persistence of infection
These mechanisms are still being investigated.
Links to Other Neurologic Conditions
Elevated chemokines, including CCL19 and CXCL13, have also been observed in other inflammatory neurologic conditions such as multiple sclerosis and neuroborreliosis.
This suggests that similar immune pathways may be involved across different diseases.
Implications for Care
Understanding immune markers like CCL19 may help identify patients at higher risk for persistent symptoms.
Management strategies discussed in the literature include:
- Symptom-based treatments for pain and fatigue
- Behavioral and cognitive interventions
- Further evaluation in selected cases
Some clinicians have explored additional antibiotic therapy in certain situations, although this approach remains an area of ongoing study.
Clinical Perspective
CCL19 provides insight into the immune response associated with Lyme disease and its chronic manifestations.
While not yet a routine clinical test, it highlights the role of immune signaling in persistent symptoms.
Patients may benefit from understanding persistent symptoms, reviewing testing limitations, and considering neurologic Lyme disease when symptoms continue.
Frequently Asked Questions
What is CCL19 in Lyme disease?
CCL19 is an immune signaling molecule that has been associated with persistent symptoms following Lyme disease.
Does a high CCL19 level mean infection is still present?
Not necessarily. Elevated levels may reflect immune activity, inflammation, or other mechanisms that are still being studied.
Can CCL19 predict long-term symptoms?
Studies suggest that higher levels may be associated with an increased risk of PTLDS.
References
- Aucott JN et al. Clin Vaccine Immunol. 2016.
- Wormser GP et al. Clin Infect Dis. 2006.
- Kowarik MC et al. J Neuroinflammation. 2012.
Dr. Daniel Cameron, MD, MPH
Lyme disease clinician with over 30 years of experience and past president of ILADS.
Symptoms • Testing • Coinfections • Recovery • Pediatric • Prevention
Is there anywhere in Canada you can have your chemokine levels, or Interlukin levels tested? I love that we are making progress in research but it hasn’t trickled down to real world applications yet. Thanks Dr Cameron for all you do!!!
I am not sure where to order them. They can be difficult to interpret as the levels fluctuate.
Can Lyme Disease cause a positive (Monoclonal) peripheral blood T-Cell Rearrangement result?
I have not it. That would be good question if you could find a hematologist with experience treating Lyme disease.